Syndax Pharmaceuticals Inc【SNDX】株式ニュース

個人投資家向けのプロ仕様のツール。

プレミアム

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

– Real-world study of revumenib shows 82% (9/11) ORR and 64% (7/11) CR/CRh rate among R/R NPM1m or KMT2Ar...

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

– High response rates observed with the all-oral combination in a heavily pretreated population, including 88...

Form 8-K - Current report

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax”) (NASDAQ: SNDX), a...

Form 4 - Statement of changes in beneficial ownership of securities

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

– Pooled analysis of 24 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who resumed revumenib...

Form 144 - Report of proposed sale of securities

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage...

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m...

georgie18 7月前

SNDX...$17.75...🥳...Cup N Handle in play here...

georgie18

Member Level
Re: georgie18 post# 400102

Friday, October 24, 2025 4:26:12 PM

Post#
400107
of 400720
SNDX...$13.30...🥳...Added on the Cup N Handle with $24 Target Price... https://schrts.co/zgGFbNEp

👍️0

georgie18 7月前

SNDX...$17.72...Hod...🥳

georgie18

Member Level
Re: georgie18 post# 704413

Tuesday, November 11, 2025 1:32:18 PM

Post#
705476
of 705497
SNDX...$17.26...🥳

georgie18

Member Level
Re: georgie18 post# 400411

Tuesday, November 04, 2025 10:38:32 AM

Post#
400464
of 400713
SNDX...$14.78...🥳

georgie18

Member Level
Re: georgie18 post# 704324

Monday, November 03, 2025 9:34:59 AM

Post#
704413
of 704586
SNDX...$14.12...🥳

georgie18

Member Level
Re: georgie18 post# 400370

Friday, October 31, 2025 2:44:13 PM

Post#
400373
of 400410
SNDX...$14.04...🥳

georgie18

Member Level
Re: georgie18 post# 704096

Friday, October 31, 2025 2:02:01 PM

Post#
704315
of 704323
SNDX...🥳...Giving off multiple trades from $13.30 range to $13.90 range

👍️0

georgie18 7月前

SNDX...$17.26...🥳

georgie18

Member Level
Re: georgie18 post# 400411

Tuesday, November 04, 2025 10:38:32 AM

Post#
400464
of 400713
SNDX...$14.78...🥳

georgie18

Member Level
Re: georgie18 post# 704324

Monday, November 03, 2025 9:34:59 AM

Post#
704413
of 704586
SNDX...$14.12...🥳

georgie18

Member Level
Re: georgie18 post# 400370

Friday, October 31, 2025 2:44:13 PM

Post#
400373
of 400410
SNDX...$14.04...🥳

georgie18

Member Level
Re: georgie18 post# 704096

Friday, October 31, 2025 2:02:01 PM

Post#
704315
of 704323
SNDX...🥳...Giving off multiple trades from $13.30 range to $13.90 range

👍️0

georgie18 7月前

SNDX...$14.78...🥳

georgie18

Member Level
Re: georgie18 post# 704324

Monday, November 03, 2025 9:34:59 AM

Post#
704413
of 704586
SNDX...$14.12...🥳

georgie18

Member Level
Re: georgie18 post# 400370

Friday, October 31, 2025 2:44:13 PM

Post#
400373
of 400410
SNDX...$14.04...🥳

georgie18

Member Level
Re: georgie18 post# 704096

Friday, October 31, 2025 2:02:01 PM

Post#
704315
of 704323
SNDX...🥳...Giving off multiple trades from $13.30 range to $13.90 range

👍️0

georgie18 7月前

SNDX...$14.12...🥳

georgie18

Member Level
Re: georgie18 post# 400370

Friday, October 31, 2025 2:44:13 PM

Post#
400373
of 400410
SNDX...$14.04...🥳

georgie18

Member Level
Re: georgie18 post# 704096

Friday, October 31, 2025 2:02:01 PM

Post#
704315
of 704323
SNDX...🥳...Giving off multiple trades from $13.30 range to $13.90 range

👍️0

georgie18 7月前

SNDX...$14.04...🥳

georgie18

Member Level
Re: georgie18 post# 704096

Friday, October 31, 2025 2:02:01 PM

Post#
704315
of 704323
SNDX...🥳...Giving off multiple trades from $13.30 range to $13.90 range

👍️0

georgie18 7月前

SNDX...🥳...Giving off multiple trades from $13.30 range to $13.90 range

👍️0

georgie18 7月前

SNDX...$13.92...🥳

georgie18

Member Level
Re: georgie18 post# 703513

Monday, October 27, 2025 9:37:47 AM

Post#
703593
of 704094
SNDX...$13.72...🥳

georgie18

Member Level
Re: georgie18 post# 400102

Friday, October 24, 2025 4:26:12 PM

Post#
400107
of 400133
SNDX...$13.30...🥳...Added on the Cup N Handle with $24 Target Price... https://schrts.co/zgGFbNEp

👍️0

georgie18 7月前

SNDX...$13.72...🥳

georgie18

Member Level
Re: georgie18 post# 400102

Friday, October 24, 2025 4:26:12 PM

Post#
400107
of 400133
SNDX...$13.30...🥳...Added on the Cup N Handle with $24 Target Price... https://schrts.co/zgGFbNEp

👍️0

georgie18 8月前

SNDX...$13.30...🥳...Added on the Cup N Handle with $24 Target Price... https://schrts.co/zgGFbNEp

👍️0

georgie18 8月前

SNDX...In on the $13.10 dip...🥳

👍️0

dinogreeves 2年前

Have you looked at TIL on Friday.

SNDX had the highest volume today for some reason, this is either going to tank hard on Monday or hit 30...50....60 dollars. Took my chances with 600 shares.

👍️0

dinogreeves 3年前

Possibly a huge run on Monday, very possible or they missed the trial. Huge 400 million in the coffers and monster institutional ownership.

👍️0

dealerschool2006 5年前

Nice rebound today for $SNDX, beat the street and conference call was successful!!!

👍️0

dealerschool2006 5年前

SNDX recovering from panic sale!!!

👍️0

dealerschool2006 5年前

Panic sale for SNDX on positive results...May options wide swings...

👍️0

DaytraderJohn 6年前

Its interesting how a company such as this can go on to have revenue loss of 50m+ per year. Yet still give higher ups 200k+ cash bonuses and large salaries.

They have no product revenue.

I expect shares to be diluted after earnings.

Read their 10k. I guess it's a gamble play incase one day they do get approval.

👍️0

BoilerRoom 6年前

$SNDX looks like this run is going to continue. Let’s hit $15.00 this week folks

👍️0

ClayTrader 6年前

* * $SNDX Video Chart 01-31-2020 * *

Link to Video - click here to watch the technical chart video

👍️0

BoilerRoom 6年前

$SNDX next week is going to be fun

👍️0

BoilerRoom 6年前

$SNDX Hope you guys went all in here...Have a great weekend see y’all on Monday

👍️0

BoilerRoom 6年前

$SNDX holding this baby!

👍️0

BoilerRoom 6年前

$SNDX keep climbing baby! Going be going up all next week

👍️0

BoilerRoom 6年前

$SNDX looking awesome from my call at $8.00

👍️0

BoilerRoom 6年前

$SNDX got us a runner folks!!!

👍️0

BoilerRoom 6年前

$SNDX Chomp Chomp Chomp!

News News Alert: Syndax Announces $35.0 Million Offering of Common Stock...

👍️0

whytestocks 7年前

News: $SNDX Syndax Announces $26.2 Million Offering of Common Stock and Warrants

WALTHAM, Mass. , March 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnolo...

Find out more https://marketwirenews.com/news-releases/syndax-announces-26-2-million-offering-of-common-stock-and-warrants-7897910.html

👍️0

DewDiligence 8年前

SNDX 3Q18 results—cash=$89.6M:

https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-third-quarter-2018-financial-results-and-provides-clinical-and-business-update-300744153.html

👍️0

Spartak 8年前

Well, the company is done. What a disaster.

👍️0

DewDiligence 8年前

SNDX -21%/AH on PFS failure in HR+/HER2- breast cancer:

https://finance.yahoo.com/news/syndax-host-conference-call-phase-200500374.html

The trial continues to test for statsig OS every six months until Nov 2019.

👍️0

DewDiligence 8年前

SNDX -20% on no news—sell-off could be related to recent general bearishness for PD-(L1) add-on agents, which was a theme at ESMO.

👍️0

DewDiligence 8年前

SNDX upgrades BoD:

https://www.prnewswire.com/news-releases/syndax-announces-changes-to-its-board-of-directors-300718661.html

SNDX phase-3 PFS data now expected in 4Q18 (rather than 3Q18); I essentially called this back in May (#msg-140923103, bottom):

https://www.prnewswire.com/news-releases/syndax-announces-updated-results-from-phase-2-encore-601-trial-of-entinostat-in-combination-with-keytruda-pembrolizumab-in-non-small-cell-lung-cancer-300717717.html

SNDX 2Q18 CC transcript:

https://finance.yahoo.com/news/edited-transcript-sndx-earnings-conference-152734163.html

👍️0

DewDiligence 8年前

SNDX 2Q18 items—6/30/18 cash=$98.4M…

PR:
http://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-reports-second-quarter-2018-financial

CC slides:
http://ir.syndax.com/static-files/18eaf63a-6c93-45cd-8272-60479300c153

👍️0

Spartak 8年前

When does pounding stop? Someone hummers it pretty badly.

👍️0

fsantes 8年前

Ill keep a look out for some then!... I’ve been looking as well. Thank you!

👍️0

DewDiligence 8年前

No. I generally post anything that's material.

👍️0

fsantes 8年前

Have you heard any new news on SNDX?

👍️0

fsantes 8年前

I really appreciate it. Bought some shares as one advisor mentioned it to me but keeping track of what’s going on on it

👍️0

DewDiligence 8年前

SNDX requested that the SEC keep this document in redacted form:

https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/sndx-ex101_169.htm

This was filed as an exhibit to the most recent 10-Q.

👍️0

fsantes 8年前

Do you know what’s the news that came out about? When I look it’s blank..

👍️0

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Syndax Pharmaceuticals Inc (SNDX)

個人投資家向けのプロ仕様のツール。

Syndax Pharmaceuticals Inc (SNDX) ニュース

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

Form 8-K - Current report

Form 8-K - Current report

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

SNDX Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

Syndax Pharmaceuticals Inc (SNDX)

個人投資家向けのプロ仕様のツール。

Syndax Pharmaceuticals Inc (SNDX) ニュース

Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026

Syndax Announces Publication of SAVE Data on Revuforj® (revumenib) in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML in the Journal of Clinical Oncology

Form 8-K - Current report

Form 8-K - Current report

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form 8-K - Current report

Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026

Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data

SNDX Discussion

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

無料で登録してください:

広告を削除する